itraconazole and Malignant Melanoma

itraconazole has been researched along with Malignant Melanoma in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	2 (40.00)	2.80

Authors

Authors	Studies
Chen, W; Fan, N; Song, Y; Sun, Y; Wang, S; Wang, Y; Yan, L	1
Bertran, E; Demidov, L; Forbes, H; Goodman, GR; Mathisen, M; Shin, SJ; Song, Y; Zhang, W	1
Inoue, K; Isono-Nakata, R; Nakagomi, N; Sakata, K; Tsubamoto, H	1
Li, D; Liang, G; Liu, M; Liu, W; Mei, H; Shen, Y; Wang, Q	1
Heckers, KO; Hildebrandt, G; Kiefer, I; Krastel, D; Pees, M; Schmidt, V	1

Trials

1 trial(s) available for itraconazole and Malignant Melanoma

Article	Year
Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF Clinical pharmacology in drug development, 2021, Volume: 10, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Itraconazole; Male; Melanoma; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Neoplasms; Vemurafenib; Young Adult	2021

Article

Year

Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF

Clinical pharmacology in drug development, 2021, Volume: 10, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Itraconazole; Male; Melanoma; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Neoplasms; Vemurafenib; Young Adult

2021

Other Studies

4 other study(ies) available for itraconazole and Malignant Melanoma

Article	Year
Itraconazole-Induced the Activation of Adenosine 5'-Monophosphate (Amp)-Activated Protein Kinase Inhibits Tumor Growth of Melanoma via Inhibiting ERK Signaling. Cell biochemistry and biophysics, 2022, Volume: 80, Issue:2 Topics: Adenosine; Adenosine Monophosphate; AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Humans; Itraconazole; MAP Kinase Signaling System; Melanoma	2022
Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report. BMC cancer, 2018, Jun-04, Volume: 18, Issue:1 Topics: Antineoplastic Agents; DNA, Complementary; Female; Humans; Itraconazole; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Positron-Emission Tomography; Skin Neoplasms; Tissue Array Analysis; Vaginal Neoplasms	2018
Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways. Oncotarget, 2017, Apr-25, Volume: 8, Issue:17 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Itraconazole; Melanoma; Mice; Phosphatidylinositol 3-Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay; Wnt Proteins; Xenograft Model Antitumor Assays	2017
[Malignant melanophoroma in a Hermann's tortoise (Testudo hermanni). A case report]. Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere, 2011, Volume: 39, Issue:1 Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Antifungal Agents; Ceftazidime; Fatal Outcome; Fungicides, Industrial; Imidazoles; Itraconazole; Male; Melanoma; Melanophores; Radiotherapy, Adjuvant; Skin Neoplasms; Surgical Wound Infection; Turtles	2011